News

Press Releases

May 18, 2023

Fractyl Health Unveils Groundbreaking Pre-Clinical Proof of Concept Results for its Rejuva^® Pancreatic Gene Therapy Platform for Metabolic Diseases at the American Society of Gene & Cell Therapy Congress

Rejuva device & procedure reliably and successfully targets pancreas with Adeno Associated Virus (AAV), potentially enabling gene therapy to address pancreatic diseases for the first time Rejuva platform and genet...

May 9, 2023

Fractyl Health to Present Preclinical Proof-of-Concept Data for Rejuva^® Pancreatic Gene Therapy Platform Program at the American Society of Gene & Cell Therapy Congress

LEXINGTON, Mass.--(BUSINESS WIRE)-- Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering new approaches to the treatment of type 2 diabetes (T2D), announced today that it will be presenti...

May 2, 2023

Fractyl Health to Present Scientific Updates on Revita^® and Rejuva^® Programs at Upcoming Medical Congresses

LEXINGTON, Mass.--(BUSINESS WIRE)-- Fractyl Health, a commercial-stage, organ-editing metabolic therapeutics company focused on pioneering new approaches to the treatment of type 2 diabetes (T2D), announced today that it...

Apr 24, 2023

Fractyl Health Announces the Initiation of a Global Registry Study of the Revita System™ in Patients With Inadequately Controlled Type 2 Diabetes (T2D)

Registry subjects will initially enroll in multiple hospitals in Germany, where the Revita System has already obtained a CE Mark and reimbursement through the NUB reimbursement process. LEXINGTON, Mass.--(BUSINESS WIR...

Feb 7, 2023

Fractyl Health gibt die kommerzielle Verfügbarkeit von Revita in Deutschland und das^® erste erfolgreiche Verfahren beim 25. Internationalen Endoskopie-Symposium in Düsseldorf bekannt

Der erste Patient mit Typ-2-Diabetes (T2D) erhielt Revita®in Deutschland, wo das Revita DMR System™über eine CE-Kennzeichnung und Kostendeckung im Rahmen des NUB-Erstattungsprozesses verfügt ImRahmen des 25. ...

Feb 7, 2023

Fractyl Health Announces Commercial Availability of Revita^® in Germany and Successful First Procedure at 25th Düsseldorf International Endoscopy Symposium

First patient in Germany with Type 2 Diabetes (T2D) received Revita® in Germany, where the Revita DMRSystem™ has a CE Mark and insurance coverage through the NUB reimbursement process Live demonstration of a Re...

Jan 31, 2023

Fractyl Health Provides Clinical Update on 24-Week Data from Open Label REVITA-T2Di Cohort

Revita-T2Di is an open-label cohort evaluating Revita® in patients with insulin-treated Type 2 Diabetes Revita in the T2Di cohort has been observed to be well tolerated, with clinically meaningful improvements in...

Dec 5, 2022

Fractyl Health Announced Positive Proof-of-Concept Data of Pancreatic GLP-1 Gene Therapy in a Type 2 Diabetes Animal Model at the 20th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

POC efficacy data in rodents shows that a novel adeno-associated virus (AAV) pancreatic gene therapy platform can confer dose-dependent effects on improving insulin production and reducing blood sugar Dose-depend...

Nov 2, 2022

Fractyl Health Initiates Landmark Scientific Partnership to Study Root Cause Mechanisms Underlying Type 2 Diabetes

Newly formed Erase T2D task force comprises leading scientists and pioneering scientific research to elucidate the role of the duodenum in type 2 diabetes and metabolic control Fractyl Health-supported research pr...

May 22, 2022

Fractyl Health Presents New Mechanistic Data on Revita^® DMR in Type 2 Diabetes

Patients treated with Revita experienced a 0.8%-point reduction in HbA1c along with a 33% improvement in markers of insulin sensitivity three months after undergoing the procedure Markers of insulin production cap...

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Fractyl Health disavows any obligation to update the information contained in such press releases after the date of their issuance.

Media Contact: Beth Brett, Corporate Communications
Bbrett@fractyl.com , +1 (720) 656-6544

Electronic Press Kit